ReportWire

Tag: Gizmodo Science Fair

  • Gizmodo Science Fair: A Spacecraft That Hunts Down Space Junk

    [ad_1]

    Astroscale is a 2025 Gizmodo Science Fair winner for developing a satellite designed to rendezvous with space junk, with the goal of capturing it and guiding it toward a fiery grave in Earth’s atmosphere.

    The question

    Can the space industry develop new technologies that help tackle the growing problem of debris and create a more sustainable orbital environment?

    The results

    On February 18, 2024, Astroscale launched its ADRAS-J (Active Debris Removal by Astroscale-Japan) mission on board Rocket Lab’s Electron rocket. The goal of the mission was to demonstrate its ability to approach, observe, and characterize a defunct spacecraft.

    Launch of ADRAS-J. © Astroscale

    The mission target was Japan’s H-2A rocket’s upper stage. This chunk of space junk has been in orbit for nearly 15 years, measuring approximately 36 feet long (11 meters) and weighing 6,613 pounds (3 tons). “Early in the program, we had a whole list of candidates,” Hisashi Inoue, chief engineer at Astroscale Japan, told Gizmodo. “We picked the target that wasn’t farthest away, and we also had some ground observations and information on the target and how it’s behaving.”

    Around three months after its launch, the ADRAS-J mission came within nearly 50 feet (15 meters) of the defunct rocket stage. With its unprecedented close approach, Astroscale became the first company to approach a large piece of space debris. It was a challenging feat, Inoue explained, as the debris is flying in space at a speed of 4 miles per second (7 kilometers per second), or faster than the speed of a bullet.

    As opposed to other rendezvous missions, the company could not communicate with the defunct rocket part. “This is junk, it’s not telling us where it is or how it’s moving,” he said. “So that makes it more complicated than just talking with a cooperative client.”

    Since its target is not equipped with GPS, the ADRAS-J spacecraft had to rely on limited ground-based observations to locate and rendezvous with the spent second stage. Despite the challenges, the satellite was successful in creeping up on its target and performing a fly-around to capture images and data of the upper stage.

    ADRAS-J served as a demonstration mission, paving the way for a follow-up that will attempt to remove the debris for real. For Astroscale’s second mission, the satellite will attempt to match the tumble rate of the wayward rocket, align itself, and dock with it. Once it’s docked, the satellite will grab the rocket with a robotic arm and lower its orbit using its thrusters before releasing it on a trajectory toward Earth’s atmosphere. The decommissioned vehicle will then burn up in Earth’s atmosphere, putting an end to its stint in orbit.

    Why they did it

    Millions of pieces of space debris are currently flying in Earth orbit, with roughly 1.2 million of them larger than 0.4 inches (1 centimeter), according to a recent report by the European Space Agency. That’s large enough to cause catastrophic damage to other spacecraft if it collides with them.

    “If you think about the terrestrial auto industry, there are all these different services performed after the car is used by the first person. It’s reused, refurbished, or recycled, and goes to second-hand use,” Inoue said. “But in space, you use [a spacecraft] once and you throw it away, but that’s not good for sustainability.”

    Nobu Okada founded Astroscale in 2013, focusing on orbital debris removal and in-orbit satellite servicing. The Tokyo-based company aims to reduce the growing amount of space junk not only by physically removing defunct spacecraft but also by extending the lifespan of satellites in space.

    “By combining all those things, I don’t think we, as Astroscale itself, can change the world’s sustainability, but we’re hoping this will kind of jump-start some of the servicing-type missions, and customers will endorse this way of thinking,” Inoue said. “Hopefully in the future, this will connect to sustainable use of space.”

    Why they’re a winner

    At a time when space startups are focused on launching more satellites, spacecraft, and rockets into orbit to cash in on the commercial use of space, Astroscale is one of the few companies promoting a sustainable practice that will allow others to coexist in the orbital environment.

    7642 Members Of Astroscale Japan
    Members Of Astroscale Japan © Astroscale

    The company is not only aiming to remove orbital debris but also to enable satellite inspection, relocation, refueling, and other life-extension services. Astroscale is pioneering sustainable use of Earth orbit in hopes that other companies follow suit and that governments worldwide set requirements for the use of space.

    What’s next

    Astroscale’s upcoming satellite is set for launch sometime in 2027, taking all the data and lessons learned from ADRAS-J and applying them to the follow-up mission.

    ADRAS-J2 is designed to actively remove the defunct Japanese rocket from orbit using Astroscale’s in-house robotic arm technology to capture it and lower its orbit. “We’re currently in the design phase,” Inoue said. “Eventually we’ll start getting more hardware in the lab and start testing it, and then start building the spacecraft next year.”

    The team

    Key members of the Astroscale team include Nobu Okada, founder and CEO; Chris Blackerby, chief operating officer; Mike Lindsay, chief technology officer; Nobuhiro Matsuyama, chief financial officer; Melissa Pane, mission and system engineer; Arielle Cohen, flight software engineer; and Gene Fujii, chief engineer.

    Click here to see all of the winners of the 2025 Gizmodo Science Fair.

    [ad_2]

    Passant Rabie

    Source link

  • Gizmodo Science Fair: A Stem Cell Treatment for Severely Damaged Corneas

    [ad_1]

    Scientists at Mass Eye and Ear are winners of the 2025 Gizmodo Science Fair for their research and development of an experimental stem cell therapy for severely, and supposedly permanently, injured corneas.

    The question

    Can stem cells help repair previously untreatable eye injuries?

    The results

    In a small trial of 14 patients published this March, the researchers showed it was possible to take stem cells from a person’s healthy eye and use them to safely replenish the surface of their other severely damaged cornea.

    First CALEC patient’s stem cells in culture. © Mass Eye and Ear

    18 months after the procedure, nearly all of the patients continued to show at least a partial response to the treatment and saw their vision improve, while two-thirds experienced a complete restoration of their corneal surface. No severe side effects related to the treatment were reported.

    Why they did it

    When our cornea—the transparent outer layer of the eye—is harmed by injury or infection, doctors often treat it by transplanting healthy corneal tissue from a donor, also known as a corneal graft. But sometimes, an injury is so damaging that it also wipes away the cornea’s limited supply of surface stem cells, also called limbal epithelial cells. Without these cells, people will experience symptoms like itching, pain, whitened corneas, and eventually loss of vision.

    Ge5 8621
    The team. © Mass Eye and Ear

    The team’s approach harvests corneal stem cells from the person’s healthy eye and grows them in the lab. These cultivated autologous limbal epithelial cells (CALEC) are then packaged onto a cellular tissue graft that’s transplanted to the other eye.

    “Corneal stem cell deficiency is really one of the most common causes of blindness worldwide. These stem cells create a healthy corneal epithelial cell layer, and that is compatible with good vision and no pain and just having a comfortable eye when you blink,” project leader Ula Jurkunas, associate director of the Cornea Service at Mass Eye and Ear, told Gizmodo. “And therefore, we developed this kind of stem cell therapy in response to an unmet medical need for stem cell deficiency and corneal blindness.”

    Why they’re a winner

    There is no highly effective treatment for the most severe cases of limbal stem cell deficiency, according to Jurkunas. So CALEC could offer hope to many people who otherwise had no options. And since it uses a person’s own adult stem cells, there’s no worry about the body rejecting the transplant or other ethical considerations commonly brought up with using embryonic stem cells.

    6. After Photo Of Cornea Post Calec
    After photo of cornea post-CALEC. © Mass Eye and Ear

    But more than just that, it’s breaking new ground in the world of stem cell medicine. According to the researchers, this is the first stem cell therapy of its kind in the U.S. to be used in the eye. For decades, scientists have been studying stem cells as a possible treatment for all sorts of irreversible injuries. CALEC and similar therapies could very well become some of the first bona fide examples of this approach working as intended.

    What’s next

    Jurkunas and her team are now in discussion with the Food and Drug Administration regarding CALEC’s approval, which may require additional data from a larger trial conducted across multiple research sites. They’re also in talks with potential commercial partners to license the therapy and help fund further development, including a new trial if needed.

    Outside of that, the team is still working to improve the shelf life and manufacturing of CALEC cells, which will be important to ensuring that the therapy can be shipped over longer distances.

    The team

    Jurkunas first started working on the research that gave rise to CALEC as a junior scientist in 2006, nearly 20 years ago. And while the team may bring on commercial partners for the final leg of development, CALEC’s current journey from the lab bench to the bedside has notably been made without any pharmaceutical funding. It has required the collaboration of many other researchers, however, including the scientists in Japan who initially helped Jurkunas learn how to better grow stem cells in the lab.

    “It’s taken an enormous amount of study research staff. And then there’s the physician collaborators, Reza Dana, Jia Yin, Lynette Johns; they were the main investigators in the [March 2025] study,” Jurkunas said. “And that’s Mass Eye and Ear only. Then we have Boston Children’s Hospital; we have Dana Farber; we have the JAEB Center, which is our [Contract Research Organization] that helped us with data analysis and management and all the things that you have to do to make sure the data is intact.”

    Jurkunas also pointed out that CALEC would have never come to fruition without the federal funding provided by the National Institutes of Health and the National Eye Institute—the same sort of funding that’s now being endangered by the current Trump administration.

    “I want to just remind people that the NIH does support medically transformative therapies that are de novo, they’re new,” she said. “We think of them, we work on them, and we develop them.”

    Click here to see all of the winners of the 2025 Gizmodo Science Fair.

    [ad_2]

    Ed Cara

    Source link